Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease.

Abstract

BACKGROUND A significant proportion of patients with Crohn's disease (CD) require dose escalation or fail adalimumab (ADL) therapy over time. ADL, a monoclonal antibody directed against tumor necrosis factor, is approved for treatment of CD. Understanding pharmacokinetics (PK) of ADL is essential to optimize individual dosing in daily practice. The aim of… (More)
DOI: 10.1097/FTD.0000000000000494

Topics

  • Presentations referencing similar topics